Previous 10 | Next 10 |
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today ann...
2023-05-12 17:45:30 ET Gainers: GSI Technology ( GSIT ) +16% . Telos ( TLS ) +8% . Arcturus Therapeutics Holdings ( ARCT ) +5% . Atara Biotherapeutics ( ATRA ) +4% . Health Catalyst ( HCAT ) +4% . Losers: Zapp Electric Ve...
2023-05-11 10:00:13 ET Gainers: Organogenesis ( ORGO ) +23% . Arcturus Therapeutics ( ARCT ) +14% . Phathom Pharmaceuticals ( PHAT ) +14% . Pulse Biosciences ( PLSE ) +13% . PharmaCyte Biotech ( PMCB ) +11% . Losers: ImmunityBi...
2023-05-11 08:21:38 ET Arcturus Therapeutics ( NASDAQ: ARCT ) added ~3% pre-market Thursday after H.C. Wainwright upgraded the biotech to Buy from Neutral, raising its price target to $51 from $19 per share on the potential of its COVID-19 vaccine ARCT-154. In November, Arct...
2023-05-09 22:05:23 ET Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Neda Safarzadeh – Vice President, Head-Investor Relations, Public Relations and Marketing Joseph Payne – Presi...
2023-05-09 16:05:22 ET Arcturus Therapeutics press release ( NASDAQ: ARCT ): Q1 GAAP EPS of $1.87 beats by $1.46 . Revenue of $80.29M (+1432.3% Y/Y) beats by $30.83M . For further details see: Arcturus Therapeutics GAAP EPS of $1.87 beats by $1.46, revenu...
New Drug Application (NDA) for ARCT-154, a next generation COVID-19 vaccine, was submitted in Japan, leading to potential approval in 2023 $23.6 Million advanced for the manufacturing and supply of ARCT-154 ARCT-032 Phase 1 enrollment and administration completed successfully;...
2023-05-08 14:50:16 ET Arcturus Therapeutics ( NASDAQ: ARCT ) is scheduled to announce Q1 earnings results on Tuesday, May 9th, after market close. The consensus EPS Estimate is -$0.01 and the consensus Revenue Estimate is $49.46M (vs. $5.24M last year). Over the last ...
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare disease...
2023-04-11 13:03:15 ET Summary Arcturus is executing well, utilizing strategic partnerships with CSL and Meiji to de-risk its financial position. The company has reinforced its management team by appointing a CMO and CDO, bringing valuable experience to the company's pipeline deve...
News, Short Squeeze, Breakout and More Instantly...
Arcturus Therapeutics Ltd. Company Name:
ARCT Stock Symbol:
NASDAQ Market:
Arcturus Therapeutics Ltd. Website:
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, toda...
2024-07-02 10:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for ARCT on July 2, 2024 08:19AM ET. The previous analyst recommendation was Overweight. ARCT was trading at $23.66 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with more severe disease ARCT-032 IND for Phase 2 multiple ascending dose study to be submitt...